REGNNot quite the slam dunk Regeneron wanted
Regeneron rolled out Phase 3 data on its fianlimab combo in first-line unresectable or metastatic melanoma, and the verdict is a classic biotech shrug: the trial did not reach statistical significance on the primary endpoint of progression-free survival. In other words, the biggest box on the regulatory checklist stayed unchecked.
The good news hiding inside the meh
There was a bright spot, though. The high-dose fianlimab combination showed a 5.1-month improvement in median PFS versus pembrolizumab monotherapy. That’s not nothing — it’s the sort of number that keeps your ear perked up at the conference podium — but it wasn’t enough to win the primary endpoint race.
Why investors should care
This matters because melanoma is a serious commercial opportunity, and LAG-3 has been one of oncology’s more buzzed-about mechanisms. But biotech investors know the drill: one strong-looking subgroup or secondary metric doesn’t automatically turn into a label, a launch, or a stock re-rating.
The company also said a separate Phase 3 head-to-head trial of the high-dose fianlimab combo versus Opdualag is still ongoing, so this story isn’t over. Big picture: Regeneron still has a live shot at making fianlimab matter — it just won’t be doing victory laps off this readout.